Joy Ghosh Email & Phone Number

United States

London, England, GB

London, UK, GB

Cambridge, Massachusetts, US

San Diego, CA, US

New York, New York, US

La Jolla, CA, US

Boston, MA, US

• Managed a value-based and innovation-focused public-private portfolio of ~60+ investments across Life Sciences and Healthcare with an AUM of $1.5B+.
• Led idea generation, diligence, negotiations, deal structuring, syndication, and managing investments across firm’s healthcare funds.
• Led firm's private investments in Annexon Biosciences, a pioneer in autoimmune and neurological diseases, Freeline Therapeutics, a clinical stage gene therapy company, Vectiv Bio, a clinical stage rare disease company.
• Board Director on Arch Oncology, BioSplice Therapeutics, Goldfinch Bio, Korro Bio, Prometheus Biosciences. Served on audit, science, and strategic financing and transaction committees.
• Board Observer on DiCE Therapeutics, Lexeo Therapeutics, and Shoreline Biosciences
• Led recruitment and training of healthcare team comprising of Ph.Ds, MDs, and CFAs.

Cambridge, Massachusetts, US

San Diego, California, US

Boston, MA, US

• Pro-actively sourced and drove investment (diligence, term sheet negotiation, syndicate building) in ViaCyte, a stem cell therapy focused company developing cures for diabetes (acquired for $320M), Annexon Biosciences.

Boston, MA, US

• Co-led 2 completed deals currently in portfolio. First deal was an investment in a publicly traded depression focused small molecule company. Second deal was an investment in a private company developing a monoclonal.
• Successfully co-led investment process through internal investment committee for 2 deals that didn't end up in portfolio due to deal dynamics.

South San Francisco, California, US

Cambridge, MA, US

• Led therapeutic area (Ophthalmology, Rare Neurological and Neuromuscular diseases) efforts to screen, evaluate, and prioritize external opportunities for collaborations, partnerships, in-licensing, and acquisitions.
• Co-led search and evaluation of small molecule and protein/antibody identification, screening, and optimization technologies for collaborations, in-licensing, and acquisitions.
• Co-led cross-functional due diligence teams including scientific, clinical, technical, finance, and commercial representatives to assess external technologies and products.
• Developed and maintained relationships with key internal stakeholders including senior executives and scientists and a wide array of external industry participants including management teams of biotech companies.

Basel, Baselstadt, CH

• Team was responsible for assessing external in-licensing and partnering opportunities and proposing deals and strategies to internal stakeholders include franchise head, disease area head, and head of development.
• Provided scientific, technical, and strategic analyses on external opportunities. Areas of input included manufacturing, design of appropriate toxicology and pharmacology studies, intellectual property, and clinical.

Basel, Baselstadt, CH

• Global Project Team Leader – Long-Acting Antibody and Protein Technologies
• Defined Target Product Profile and conceived project strategy by performing competitive and technical landscape and business value analyses.
• Expanded application and translation of technology to several indications including rheumatoid and osteoarthritis, bone regeneration, and inflammatory diseases.
• Contributed to overall therapeutic area strategy including future market positioning and life cycle management with follow-on technologies.
• Led a global cross-disciplinary team tasked with developing second generation technology to enable biological drugs to be dosed 1-2 times per year. In addition to providing scientific guidance, responsibilities include.
• Co-developed intellectual property strategy and co-authored four patents long-acting technology platform.Co-Project Team Leader for best-in-class disease-modifying biotherapeutic for Glaucoma.

Basel, Baselstadt, CH

• Global Project Team Leader – Half-life Extension Technology Platform
• Selected to lead top priority project focused on developing best-in-class long-acting biologics.
• Led team that delivered first generation long-acting molecule for first-in-human proof-of-concept studies in ~ 4 years; IND filed and approved (co-authored IND, IB, and clinical protocol). Phase I/II studies ongoing.
• Assessed overall competitive landscape and conceived novel strategy to produce clearly differentiated best-in-class technology to support the Novartis pipeline for the next 10+ years.
• Organized global strategy workshop between various global divisions (Research, Alcon, and Novartis Pharmaceuticals) to formulate long-acting and sustained release strategy for Ophthalmology.
• Authored 1 patent, 1 manuscript (in process), project reviews, and technical reports for team, disease area head, various internal decision boards, and external advisory boards.Global Project Team Leader –.

Boston, MA, US

• Project Title: “Molecular mechanisms and nanotherapeutics for neurodegenerative diseases.”
• Recruited, trained, and led a team of 3 scientists to develop novel nanotherapeutics for anemia, diabetes, Alzheimer’s disease, and Parkinson’s disease by targeting the oxidative stress pathway.
• Established and led a cross-functional collaboration with the University of Central Florida and Lockheed Martin to screen novel nanoparticles as a counter measure against radiation sickness (NASA/DOD supported).
• Performed critical validation of a novel non-invasive laser-based diagnostic platform for Alzheimer’s disease.
• Authored research grants for the Michael J Fox Foundation and National Science Foundation (~$2.5MM).
• Collaborated to elucidate the molecular mechanisms of TDP-43 and LRRK2 in Parkinson’s disease. Work resulted in J. Neuroscience paper in <3 months.

• Led company’s core scientific efforts in developing a brain permeable molecule to treat Alzheimer’s disease.
• Performed due diligence and managed relationships with CROs for company’s pre-clinical outsourcing work.
• Developed a library of small molecules as potential disease-modifying therapeutics for several neuroscience diseases.
• Co-authored and leveraged company’s business and scientific operating plan and IP portfolio to evangelize local and international investors to raise >$220,000 in seed capital.
• Negotiated exclusive license with the University of Washington Technology Transfer Office.

Seattle, WA, US

• Project Title: “Design and development of novel peptidomimetic therapeutics for protein aggregation diseases.”
• 6 first-author peer reviewed publications, 2 first-author peer reviewed international conference abstracts/presentations, and 1 international patent.
• Studied the molecular mechanisms of unfolding and aggregation diseases with a special emphasis on amyloidosis.
• Mentored 3 research assistants to successful careers in Medicine and Industry.

• Evaluated business plan, performed in-depth financial modeling and valuation, developed risk mitigation strategies, and performed due diligence of company and potential acquirers.
• Deliverables used successfully by CEO to raise $2MM in Venture Capital and establish strategic alliance with Singapore Technologies for the company’s flagship product, the People Portal II, the world's first.

Phd, Structural Biology And Neuroscience

Certificate In Entrepreneurship And Innovation, Business Administration And Management, General

B.S, Biochemistry

Certificate, Molecular Biology Of Aging

Certificate, Advanced Techniques In Molecular Neuroscience